Aspergillosis, a group of diseases caused by various species of Aspergillus fungi, presents a significant challenge in infectious diseases, with Aspergillus fumigatus being the most common causative agent. Our company is uniquely positioned to provide comprehensive support and services for researchers and scientists working in infectious diseases, such as aspergillosis.
Overview of Aspergillosis
This opportunistic fungal infection primarily targets individuals with compromised immune systems, including those with conditions such as hematological malignancies, organ transplants, or advanced HIV/AIDS. Aspergillosis can manifest in different forms, including invasive aspergillosis, chronic pulmonary aspergillosis, and allergic bronchopulmonary aspergillosis. In the general population, the incidence of invasive aspergillosis remains relatively low, typically estimated at around 0.5 to 2 cases per 100,000 individuals annually.
Fig.1 Mechanisms of action of antifungal agents active against Aspergillus spp. (Zakaria, A., et al., 2020)
Pathogenesis of Aspergillosis
Aspergillus spores are widespread in the environment and frequently inhaled by humans. In individuals with weakened immune defenses, these spores can infiltrate various organs like the lungs and sinuses, thereby instigating the development of different types of aspergillosis. Moreover, the fungus can also trigger an exaggerated immune response in some individuals, leading to allergic forms of the disease.
Vaccine Development for Aspergillosis
NXT-2 Vaccine
A recombinant peptide vaccine, based on a conserved KEX1 sequence present on multiple pathogenic fungi.
VesiVax® Af3/9
VesiVax® adjuvant liposomes were chemically conjugated with two recombinant A. fumigatus surface antigens, Asp f3 and Asp f9.
Lam-CRM Conjugate
Laminarin (a carrier protein used in some glyco-conjugate bacterial vaccines) conjugated with the diphtheria toxoid CRM197.
Therapeutics Development for Aspergillosis
| Names |
Mechanism of Action |
Targets |
Research Phase |
| Voriconazole |
Inhibit cytochrome P450-dependent lanosterol 14α-demethylase |
CYP51A1 |
Approved |
| Lsavuconazole |
Lead to fungal cell membrane structure and function disorders |
CYP51A1 |
Approved |
| Caspofungin |
Glucan synthase inhibitor |
Glucan synthase |
Approved |
| Olorofim |
Inhibits the dihydroorotate dehydrogenase |
DHODH |
Phase IIb/III trials |
| Fosmanogepix |
Gwt1 enzyme inhibitor |
Gwt1 |
Phase II trials |
| Opelconazole |
An azole optimized for inhalation |
CYP51A1 |
Phase III trials |
| Rezafungin |
An echinocandin with long half-life time |
Glucan synthase |
Phase III trials |
| Ibrexafungerp |
A glucan synthase inhibitor |
Glucan synthase |
Phase III trials |
| Recombinant IFNγ |
Increases phagocytic antifungal activity |
/ |
Preclinical research |
| Adoptive T-cell transfer |
Enhance immune response |
/ |
Preclinical research |
| CAR T-cell therapy |
Secrete IFNγ upon activation by β-glucan, hence suppressing the growth of A. fumigatus |
/ |
Preclinical research |
Our Services
Our company has a team of experienced experts with deep knowledge of fungal pathogenesis, immunology, and diagnostic development. Supported by cutting-edge facilities housing state-of-the-art technologies and an extensive platform for developing animal models, vaccines, and therapeutics, we deliver a complete solution tailored to all your aspergillosis research requirements.
Vaccine Development Platforms
Therapeutic Development Platforms
Infectious Disease Models
Our company offers a variety of animal models of aspergillosis for you to gain a comprehensive understanding of the complex pathogenesis of aspergillosis and to develop effective diagnostic and therapeutic strategies.
Animals are genetically engineered or administered chemicals (such as corticosteroids) to suppress their immune system, then challenged with Aspergillus conidia (spores) to develop aspergillosis.
Optional Models: Corticosteroid-induced model; Clec7atm1Gdb model, etc.
Trust our comprehensive services to propel your research forward and make a meaningful impact in the fight against this challenging fungal infection. If you are interested in our service, we invite you to reach out to us for further information and to obtain detailed quotations tailored to your research requirements.
Reference
- Zakaria, Ayate et al. "Recent trends in the epidemiology, diagnosis, treatment, and mechanisms of resistance in clinical Aspergillus species: A general review with a special focus on the Middle Eastern and North African region." Journal of infection and public health 13.1 (2020): 1-10.
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
